ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Provision of a written informed consent at the enrolment visit
- Men or women above 30 years of age
- Fertile women need to take contraceptives or have to be sterilised
- Diagnosed with any diabetes mellitus type 1 or type 2
- Present foot ulcer with an ulcer duration <= 12 months
- Intolerance to statins at any time in the past.
- Unwillingness to participate
- A history of alcohol or drug abuse within the last 2 years
- Foot ulcer with the etiology from vasculitis, pyoderma gangrenosum, angiodermatitis
necroticans (hypertensive ulcer), necrobiosis lipoidica, hydrostatic pressure/venous
insufficiency or any neoplasms (basalioma, kaposis sarcoma, squamous cell carcinoma
etc).
- History of drug-induced hepatitis or previous liver enzyme elevations (> 3 times the
upper limit of normal) while taking statins.
- History of drug-induced creatine phosphokinase (CPK) > 3 times the upper limit of
normal.
- Critical limb ischemia that requires re-vascularisation procedures within 2 months
- Brachial-ankle index < 0.5
- Other serious or unstable medical or psychological conditions that, in the opinion of
the investigator, would compromise the patient's safety or successful participation in
the trial.
- Any clinically significant abnormality identified in the enrolment medical history,
physical examination, laboratory test which, in the judgement of the investigator,
would preclude safe completion of the study.
- Active liver disease or hepatic dysfunction defined as ALAT or ASAT elevations > 2
times the upper limit of normal or total bilirubin > 1.5 times the upper limit of
normal.
- Pregnancy
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- RUD,
- Sarpsborg,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Improving Diabetic Foot Ulcers With Atorvastatin | |||
Official Title ICMJE | Improving Diabetic Foot Ulcers With Atorvastatin | |||
Brief Summary | Lower limb complications are a substantial matter in the diabetic population and studies show that the annual incidence of foot ulcers ranges from 1.0-4.1% while the cumulative lifetime incidence is approximately 15%. Foot ulcers may become complicated by infection or gangrene, and ultimately result in amputation. In addition, foot ulcers have a significant impact on quality of life (QoL). The treatment of diabetic foot ulcers has not made substantial progress in recent years with regards to improved healing although there have been several actions taken to update the process. The current practice consists of wound debridement, treatment of underlying infections and pressure relief. This trial investigates the adjunctive effects of high (80 mg) or low (10 mg) dose atorvastatin to conventional treatment on the healing of diabetic foot ulcers. | |||
Detailed Description | The diabetic foot ulcer etiology is multiplex and the wound healing is often not very successful due to various reasons. The ulcer's etiology is associated with peripheral vascular disease, autonomic neuropathy and endothelial. There may also be present some metabolic conditions that are not optimal for wound-healing, delaying the process even more (hyperglycemia, hyperlipidemia, hyperinsulinemia, pro-coagulative state). It has been shown that statins may improve these aspects making the use of this as adjuvant therapy in treating diabetic foot ulcers an interesting theory. There is so far not any direct evidence for this, although documentation exists for several other possible associated conditions. This study aims to elucidate the pleiotropic effects of atorvastatin on the healing of diabetic foot ulcers. Material and Methods: This 26-week prospective randomised, open, study will be conducted as a pilot to assess the efficacy of atorvastatin in improving diabetic foot-ulcer healing. Atorvastatin will be given in two dosages (10 mg and 80 mg) and evaluations between these groups will be done with regards to improvement in foot ulcer healing, microcirculation and inflammatory markers. We aim to include 24 patients with diabetes (both type 1 and 2), over the age of 30, of both genders who have a wound duration of less than 12 months. The patients will be recruited from the diabetic out-patient clinics in two centers (Sarpsborg Hospital and Asker and Baerum Hospital). Study Plan: We plan to begin the enrolment of eligible patients in autumn 2004. We plan for a 18 month inclusion period and hope to conclude this pilot study by autumn 2006. Results from the study will be presented in international papers or meetings concerning diabetes and complications. | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 2 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE |
| |||
Intervention ICMJE | Drug: Atorvastatin (10 mg or 80 mg) | |||
Study Arms ICMJE | Not Provided | |||
Publications * | Healing of diabetic foot ulcers may be modified by high dose atorvastatin - a 6 month randomised controlled pilot trial European Association for the Study of Diabetes 2008 Johansen OE, Birkeland KI, Jørgensen AP, Orvik E, Sørgård B, Torjussen BR, Ueland T, Aukrust P, Gullestad L Diabetologia 2008;51(S1):S515. | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 13 | |||
Original Enrollment ICMJE | 20 | |||
Actual Study Completion Date ICMJE | March 2007 | |||
Actual Primary Completion Date | March 2007 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 30 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Norway | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00134550 | |||
Other Study ID Numbers ICMJE | The IDUS trial | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Odd Erik Johansen | |||
Study Sponsor ICMJE | Asker & Baerum Hospital | |||
Collaborators ICMJE | Pfizer | |||
Investigators ICMJE |
| |||
PRS Account | Asker & Baerum Hospital | |||
Verification Date | September 2009 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |